Knee pain relief showdown: Hyruan-One vs. synvisc in new study

NCT ID NCT03484091

Completed Symptom relief Sponsor: Thammasat University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a single injection of Hyruan-One works better than Synvisc or a saline placebo for knee osteoarthritis pain. 276 adults with knee osteoarthritis who had not gotten relief from other treatments took part. The main goal was to measure pain changes over 6 months using a standard pain scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hyaluronic acid (Hyruan-One and Hylan G-F 20/Synvisc)
What this could lead to: If it works, this could confirm that a single injection of Hyruan-One provides similar or better pain relief for knee osteoarthritis compared to an existing treatment.
What could go wrong: This is a completed Phase 4 trial, but results may not apply to all patients. The effect is temporary symptom relief, not a cure, and some people may not benefit or may have side effects like injection-site pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS

Contacts and locations

Locations

Thammasat University

Khlong Luang, Changwat Pathum Thani, 12120, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.